Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOR-CACTUS
2024-511223-34-00Phase 4Authorised
- Sponsor
- Diakonhjemmet Sykehus
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of triamcinolone acetonide in carpal tunnel syndrome (CTS) (2 arms), sponsored by Diakonhjemmet Sykehus. Primary endpoint: Successful treatment outcome at 12 months. Planned start Jun 2024; status: authorised.
02
Drugs
triamcinolone acetonide
03
Conditions
carpal tunnel syndrome (CTS)
Beyond the preview
Go deeper on 2024-511223-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511223-34-00.